ArticleOncotarget2017

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.

Masanobu Tsubaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.